PharVision Advisers’s Zymeworks ZYME Stock Holding History

PharVision Advisers’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,790	Closed	-$304K	–	1050
2025 Q3	$304K	Buy	+17,790	New	+$255K	0.17%	220

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PharVision Advisers's ZYME Position: Q4 2025 in Review

PharVision Advisers sold out of Zymeworks (ZYME) in Q4 2025, closing a stake of 17,790 shares — an estimated $304K sold.

PharVision Advisers first reported a position in ZYME in Q3 2025 and held it in 1 quarter. The position peaked at $304K in Q3 2025. 209 funds tracked by Wall St. Rank hold ZYME as of Q4 2025.

PharVision Advisers reported no remaining Zymeworks position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 17,790 Zymeworks shares in Q4 2025, an estimated $304K.
PharVision Advisers first reported a position in Zymeworks in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Zymeworks position peaked at $304K in Q3 2025.
209 funds tracked by Wall St. Rank held Zymeworks as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.